发明名称 |
CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLS AND CYTOKINES |
摘要 |
<p>In a cancer treatment combining cell therapy with chemotherapy, autologous CD8+ T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating antigen- specific activated cytotoxic T lymphocytes. Such activated CTLs are administered to the patient in conjunction with a lymphodepletion and CTL maintenance regimen comprising a non-myeloblative but lymphdepleting agent, such as cladribine or denileukin diftitox, and interleukin-2 and interferon-.alpha.-2b stimulatory cytokines.</p> |
申请公布号 |
CA2643337(C) |
申请公布日期 |
2016.01.12 |
申请号 |
CA20072643337 |
申请日期 |
2007.02.23 |
申请人 |
JANSSEN PHARMACEUTICA N.V. |
发明人 |
CAI, ZELING;MORIARTY, ANN;PETERSON, PER A.;RICHARDS, JON M. |
分类号 |
A61K38/19;A61K31/7076;A61K38/17;A61P35/00 |
主分类号 |
A61K38/19 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|